Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer's Disease.
- DOI
- 10.3390/ph16111620
- Published
- 2023 Nov 16
- Container
- Pharmaceuticals (Basel, Switzerland)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3390/ph16111620,
title = {Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer's Disease.},
author = {Stanciu GD and Ababei DC and Solcan C and Bild V and Ciobica A and Beschea Chiriac SI and Ciobanu LM and Tamba BI},
year = {2023},
journal = {Pharmaceuticals (Basel, Switzerland)},
doi = {10.3390/ph16111620},
url = {https://doi.org/10.3390/ph16111620}
}RIS
TY - JOUR TI - Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer's Disease. AU - Stanciu GD AU - Ababei DC AU - Solcan C AU - Bild V AU - Ciobica A AU - Beschea Chiriac SI AU - Ciobanu LM AU - Tamba BI PY - 2023 JO - Pharmaceuticals (Basel, Switzerland) DO - 10.3390/ph16111620 UR - https://doi.org/10.3390/ph16111620 ER -
APA
GD, S., DC, A., C, S., V, B., A, C., SI, B. C., LM, C., & BI, T. (2023). Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer's Disease.. Pharmaceuticals (Basel, Switzerland). https://doi.org/10.3390/ph16111620
Source records
- pubmed · retrieved 2026-09-26T05:37:56.175Z